ArticleDisease markers2015
Novel Serum Biomarkers to Differentiate Cholangiocarcinoma from Benign Biliary Tract Diseases Using a Proteomic Approach.
Article in Disease markers, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 42 citations in OpenAlex.
- Can Adipokine FAM19A5 Be a Biomarker of Metabolic Disorders?Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
- Phosphorylated Proteins from Serum: A Promising Potential Diagnostic Biomarker of Cancer.International journal of molecular sciences · 2022Review
- Gastrointestinal and Pancratohepatobiliary Cancers: A Comprehensive Review on Epidemiology and Risk Factors Worldwide.Middle East journal of digestive diseases · 2022Review
- KRAB-ZFP Transcriptional Regulators Acting as Oncogenes and Tumor Suppressors: An Overview.International journal of molecular sciences · 2021Review
- Quantitative proteomic analysis of bile in extrahepatic cholangiocarcinoma patients.Journal of Cancer · 2020Article
- A Prognostic Model Based on RNA Binding Protein Predicts Clinical Outcomes in Hepatocellular Carcinoma Patients.Frontiers in oncology · 2020Article
- Association of Serum FAM19A5 with Cognitive Impairment in Vascular Dementia.Disease markers · 2020Article
- TAFA5 promotes proliferation and migration in gastric cancer.Molecular medicine reports · 2019Article
- Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases.Clinical epigenetics · 2019Article
- Translational Bioinformatics for Cholangiocarcinoma: Opportunities and Challenges.International journal of biological sciences · 2018Review
- FAM19A5, a brain-specific chemokine, inhibits RANKL-induced osteoclast formation through formyl peptide receptor 2.Scientific reports · 2017Article
- Next-generation sequencing traces human induced pluripotent stem cell lines clonally generated from heterogeneous cancer tissue.World journal of stem cells · 2017Article
- Serum and tissue markers in hepatocellular carcinoma and cholangiocarcinoma: clinical and prognostic implications.Oncotarget · 2017Review
- Characterization of Gene Expression Patterns among Artificially Developed Cancer Stem Cells Using Spherical Self-Organizing Map.Cancer informatics · 2016Article
- From Normal Skin to Squamous Cell Carcinoma: A Quest for Novel Biomarkers.Disease markers · 2016Review
- Gene Expression and Proteome Analysis as Sources of Biomarkers in Basal Cell Carcinoma.Disease markers · 2016Review
- An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma.International journal of genomics · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimCholangiocarcinoma (CCA) is the most frequent biliary malignancy, which poses high mortality rate due to lack of early detection. Hence, most CCA cases are present at the advanced to late stages with local or distant metastasis at the time of diagnosis. Currently available tumor markers including CA19-9 and CEA are inefficient and of limited usage due to low sensitivity and specificity. Here, we attempt to identify serum tumor markers for CCA that can effectively distinguish CCA from benign biliary tract diseases (BBTDs).
methodsSerum samples from 19 CCA patients and 17 BBTDs were separated by SDS-PAGE followed with LC-MS/MS and were subjected to statistical analysis and cross-validation to identify proteins whose abundance was significantly elevated or suppressed in CCA samples compared to BBTDs.
resultsIn addition to identifying several proteins previously known to be differentially expressed in CCA and BBTDs, we also discovered a number of molecules that were previously not associated with CCA. These included FAM19A5, MAGED4B, KIAA0321, RBAK, and UPF3B.
conclusionsNovel serum biomarkers to distinguish CCA from BBTDs were identified using a proteomic approach. Further validation of these proteins has the potential to provide a biomarker for differentiating CCA from BBTDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.